ReviewBMC cancer2011
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Review in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.Cancer reports (Hoboken, N.J.) · 2026Article
- Skull base chordomas - emphasis on surgical strategy and recurrence-free survival.Medicine and pharmacy reports · 2025Article
- Chordoma: Genetics and Contemporary Management.International journal of molecular sciences · 2024Review
- Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors.Current oncology reports · 2024Review
- AZD8055 enhances in vivo efficacy of afatinib in chordomas.The Journal of pathology · 2021Article
- Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma.Clinical sarcoma research · 2020Article
- Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.Disease models & mechanisms · 2019Article
- Solamargine inhibits proliferation and promotes apoptosis of CM-319 human chordoma cells through suppression of notch pathway.Translational cancer research · 2019Article
- Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.Frontiers in oncology · 2019Article
- Chordoma of the Head and Neck: A Review.Head and neck pathology · 2018Review
- EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature.Translational medicine @ UniSa · 2017Article
- EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.The Journal of pathology · 2016Article
- Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series.Clinical sarcoma research · 2016Article
- Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.Frontiers in oncology · 2016Article
- Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.Neurosurgical review · 2015Article
- Novel targeted therapies in chordoma: an update.Therapeutics and clinical risk management · 2015Review
- A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12.Disease models & mechanisms · 2014Article
- Molecular profiling of chordoma.International journal of oncology · 2014Article
- Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.Journal of neurosurgery · 2014Article
- Isolated liver metastasis of sacrococcygeal chordoma: case report and review of the literature.Case reports in oncological medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of the notochord. They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity. CASE PRESENTATION: We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that progressed on imatinib and subsequently responded to erlotinib during 12 months.
conclusionsWe report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the literature concerning the rationale and potential of EGFR targeting in chordoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.